INTRODUCTION We evaluated 8, 12, or 24 weeks of ledipasvir/sofosbuvir in patients with hepatitis C virus and end-stage renal disease undergoing dialysis. METHODS Primary efficacy end point was sustained virologic response 12 weeks after treatment. Primary safety end point was treatment discontinuation because of adverse events (AEs). RESULTS Ninety-four percent (89/95) achieved sustained virologic response 12 weeks after treatment. Six patients died during treatment (n = 4) or before study completion (n = 2); no deaths were related to treatment. No patients discontinued treatment because of AEs. Thirteen percent had serious AEs; none were related to treatment. DISCUSSION Treatment with ledipasvir/sofosbuvir was safe and effective in patients with end-stage renal disease undergoing dialysis.

中文翻译：

---

Ledipasvir/Sofosbuvir 治疗因终末期肾病而接受透析的丙型肝炎患者，疗程为 8、12 或 24 周。

引言 我们对接受透析的丙型肝炎病毒伴终末期肾病患者的雷迪帕韦/索磷布韦治疗 8、12 或 24 周进行了评估。方法 主要疗效终点是治疗后 12 周的持续病毒学应答。主要安全终点是因不良事件（AE）而停止治疗。结果 94% (89/95) 在治疗 12 周后达到持续病毒学应答。6 名患者在治疗期间 (n = 4) 或研究完成之前 (n = 2) 死亡；没有死亡与治疗有关。没有患者因 AE 而停止治疗。13% 存在严重 AE；没有一个与治疗有关。讨论 雷迪帕韦/索磷布韦治疗对于接受透析的终末期肾病患者是安全有效的。